You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Phase II Trial of Erlotinib during and after Radiotherapy in Children with Newly Diagnosed High-Grade Gliomas
|
|---|---|
| Published in |
Frontiers in oncology, April 2014
|
| DOI | 10.3389/fonc.2014.00067 |
| Pubmed ID | |
| Authors |
Ibrahim Qaddoumi, Mehmet Kocak, Atmaram S. Pai Panandiker, Gregory T. Armstrong, Cynthia Wetmore, John R. Crawford, Tong Lin, James M. Boyett, Larry E. Kun, Fredrick A. Boop, Thomas E. Merchant, David W. Ellison, Amar Gajjar, Alberto Broniscer |
| Abstract |
Epidermal growth factor receptor is overexpressed in most pediatric high-grade gliomas (HGG). Since erlotinib had shown activity in adults with HGG, we conducted a phase II trial of erlotinib and local radiotherapy (RT) in children with newly diagnosed HGG. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 57 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 57 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 10 | 18% |
| Researcher | 7 | 12% |
| Student > Bachelor | 7 | 12% |
| Student > Master | 5 | 9% |
| Student > Doctoral Student | 4 | 7% |
| Other | 11 | 19% |
| Unknown | 13 | 23% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 24 | 42% |
| Biochemistry, Genetics and Molecular Biology | 6 | 11% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 5% |
| Neuroscience | 3 | 5% |
| Immunology and Microbiology | 2 | 4% |
| Other | 4 | 7% |
| Unknown | 15 | 26% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 April 2014.
All research outputs
#20,233,045
of 25,728,855 outputs
Outputs from Frontiers in oncology
#9,476
of 22,769 outputs
Outputs of similar age
#168,528
of 239,960 outputs
Outputs of similar age from Frontiers in oncology
#35
of 69 outputs
Altmetric has tracked 25,728,855 research outputs across all sources so far. This one is in the 18th percentile – i.e., 18% of other outputs scored the same or lower than it.
So far Altmetric has tracked 22,769 research outputs from this source. They receive a mean Attention Score of 3.0. This one is in the 49th percentile – i.e., 49% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 239,960 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 26th percentile – i.e., 26% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 69 others from the same source and published within six weeks on either side of this one. This one is in the 42nd percentile – i.e., 42% of its contemporaries scored the same or lower than it.